Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Tobin
Mary
M
thetgi@aol.com
D000279:Administration, Cutaneous; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000451:nursing*; D004347:Drug Interactions; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012642:Selegiline / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014439:Tyramine / Q000009:adverse effects
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D014439:Tyramine